Purpose: To our knowledge it is unknown whether urinary biomarkers for prostate cancer have added utility to clinical risk calculators in different racial groups. We examined the utility of urinary biomarkers added to clinical risk calculators for predicting prostate cancer in African American and nonAfrican American men. Materials and Methods: Demographics, PCPT (Prostate Cancer Prevention Trial) risk scores, data on the biomarkers data PCA3 (prostate cancer antigen 3) and T2ERG (transmembrane protease serine 2 and v-ets erythroblastosis virus E26 oncogene homolog gene fusion), and biopsy pathology features were prospectively collected on 718 men as part of EDRN (Early Detection Research Network). Utility was determined by generating ROC curves and comparing AUC values for the baseline multivariable PCPT model and for models containing biomarker scores. Results: PCA3 and T2ERG added utility for the prediction of prostate cancer and clinically significant prostate cancer when combined with the PCPT Risk Calculator. This utility was seen in nonAfrican American men only for PCA3 (AUC 0.64 increased to 0.75 for prostate cancer and to 0.69e0.77 for clinically significant prostate cancer, both p <0.001) and for T2ERG (AUC 0.64e0.74 for prostate cancer, p <0.001, and 0.69e0.73 for clinically significant prostate cancer, p ¼ 0.029). African American men did not have an added benefit with the addition of biomarkers, including PCA3 (AUC 0.75e0.77, p ¼ 0.64, and 0.65e0.66, p ¼ 0.74) and T2ERG (AUC 0.75e0.74, p ¼ 0.74, and 0.65e0.64, p ¼ 0.88), for prostate cancer and clinically significant prostate cancer, respectively.
PROSTATE cancer screening is the most controversial area in urological oncology. The risks of over diagnosis and resultant overtreatment have been well documented and the contribution of PSA screening in decreasing mortality remains unproven. 1 However, almost 30,000 American men were expected to die from PCa in 2014. 2 The debate has put the utility of PSA for detection of PCa under scrutiny. Despite its value in clinical practice, PSA has limits as a biomarker in that it lacks specificity and sensitivity in the detection of PCa. 3 Incidence rates of PCa are higher in AA men compared to all other racial groups. 2 AA men present with more aggressive disease 4 and have the highest PCa related death rates among ethnic groups. 2 Several factors have been proposed for this racial disparity, including biological factors as well as access to health care. 5, 6 Research has uncovered promising biomarkers in PCa. Among them PCA3 and T2ERG have been used to improve prediction models such as PCPT RC. The utility of biomarkers in specific racial groups, however, is unknown.
Against the backdrop of well-known racial variations in detection and biology, we evaluated the added utility of urinary PCA3 and/or T2ERG to baseline clinical risk calculator model, PCPT RC, among AA and nonAA men in the EDRN cohort.
PATIENTS AND METHODS

Patient Population
A total of 733 men were invited to participate in the institutional review board approved EDRN study from December 2009 to June 2011. 7, 8 Participants had to have 1 or more of certain indications, including elevated/ increasing PSA, less than 15% free PSA, positive family history, prior atypical small acinar proliferation or high grade prostate intraepithelial neoplasia and/or abnormal DRE. Men participating in an intervention trial for prostate disease and those with a history of prior prostate surgery, prior saturation or any prostate biopsy within 6 months and prior exposure to PCA3 testing were excluded. Race was patient self-reported and categorized as AA and nonAA for analysis.
Post-DRE urine was prospectively collected from men presenting for transrectal ultrasound guided biopsy at 3 EDRN sites (Harvard, University of Michigan and Weill-Cornell). A total of 15 men were excluded for ineligibility after consent (prior surgery or biopsy, or did not meet other inclusion criteria), inadequate urine sample, uninformative PCA3/T2ERG, no biopsy, missing PCPT RC component, PSA or missing biopsy information and metastatic disease at presentation. The remaining 718 men had complete demographic, urinary biomarker and biopsy data available. Investigators at each site were blinded to biomarker results.
Specimen Collection and Assays
PCA3. Specimens for PCA3 were collected after DRE with manipulation and processed as described previously. 7 The ratio of urinary PCA3 to PSA mRNA was used to generate the PCA3 score. T2ERG. Urinary T2ERG was determined using a previously described second-generation TMPRSS2:ERG assay.
10 T2ERG scores were calculated as mean urine T2ERG to PSA mRNA.
Outcome Measures
Biopsy Data. Transrectal ultrasound biopsies were performed using a standard template. Specimens were reviewed at each clinical site. However, 10% of samples were randomly selected for independent review by a central pathologist. Variables of each patient were input into the published regression model, PCPT RC 1.0, which gave risk estimates for individual patients for PCa and CS PCa.
Statistical Analysis
The primary outcome was the presence of any PCa or CS PCa. For continuous variables the mean AE SD or median and IQR were compared between subgroups using the 2-sample t-test or the Mann-Whitney U test, respectively. For categorical variables proportions were compared between groups using the chi-square or Kruskal-Wallis test.
ROC curves were generated for each group to compare predictive performance of PCPT RC (base model) and with PCA3 and/or T2ERG via logistic regression models. The AUC method was used to compare the base model of PCPT RC alone with models including PCA3 and/or T2ERG in the 2 groups. Similar analyses were performed for CS PCa utilizing CS PCPT RC. AUCs were compared by the DeLong method. Power estimation was performed, using an a of 0.05 and a population size of 72 for AA men, to determine if there existed sufficient power to detect a 10% variation in AUC after adding the biomarkers to the PCPT RC. Analyses were performed with StataÒ, version 14.0.
RESULTS
Demographics, Urinary Biomarkers and Risk Calculators
Of 718 men 646 (90%) were nonAA and 72 (10%) were AA. The supplementary table (http://jurology. com/) lists prebiopsy serum PSA and prognostic scores among the subgroups with PCA3 and T2ERG further stratified by the presence or absence of PCa on biopsy. There were significantly higher PCA3, PCPT RC and CS PCPT RC scores in AA vs nonAA men (p <0.001, 0.041, <0.001, respectively). T2ERG scores were higher in nonAA men but this was not significant (p ¼ 0.200). Higher PCA3 and T2ERG scores were seen in patients with positive biopsy (both p <0.001. Furthermore, nonAA men had higher T2ERG than AA men in those with positive biopsies (p ¼ 0.015). Conversely, AA men had higher PCA3 levels in those with negative biopsy (p ¼ 0.011) but not significantly in those with positive biopsy vs nonAA men (0.282).
Biopsy Pathology
On biopsy 324 (45%) and 194 men (27%) were found to have PCa and CS PCa, respectively. AA men were not found to have a significantly higher rate of PCa or CS PCa (p ¼ 0.104 and 0.121, respectively). The median total number of cores and of positive cores was not different between the groups (table 1). The distribution of Gleason scores did not differ between AA and nonAA men (0.952). Figure 1 shows ROC curves for the models for both groups. ROC curves generated AUC values for baseline PCPT RC with or without urinary biomarkers (table 2) . PCA3 demonstrated added utility in nonAA men with an increase in the AUC. However, among AA men there was no significant increase in AUC (table 2 and fig. 1, A) . Adding T2ERG to PCPT RC failed to demonstrate significant added utility in AA men but it was significantly improved among nonAA men (table 2 and fig. 1, B) .
Prostate Cancer Prevention Trial Risk Calculator and Biomarkers
The combination of PCA3 and T2ERG also demonstrated added utility in nonAA men (table 2  and fig. 1, C ) . The addition of PCA3 and T2ERG combined, when compared to the addition of PCA3 or T2ERG alone, showed a significantly improved detection ability in nonAA men (both p <0.001). The combination of the 2 urinary biomarkers to PCPT RC failed to show added utility over baseline PCPT RC in AA men. Figure 2 shows ROC curves for CS PCPT RC with the addition of PCA3 and/or T2ERG. Table 2 lists model AUCs for subgroups. PCA3, T2ERG and the combination demonstrated added utility above the baseline risk calculator, CS PCPT RC in this case, in nonAA men but failed to show benefit in AA men ( fig. 2) . Additionally, the combination of PCA3 and T2ERG was better at improving CS PCa detection than T2ERG alone was in nonAA men (p <0.001). There was no significant improvement when using both biomarkers vs PCA3 for CS PCa in nonAA men (p ¼ 0.073).
Clinically Significant Prostate Cancer Prevention Trial Risk Calculator and Biomarkers
DISCUSSION
Biomarkers are quantifiable measures of a cellular or molecular alteration that may be involved in biological pathways. They have shown potential to assist in screening, diagnosing, prognosticating and monitoring the response to treatment. 12 This study examined the added utility of 2 urinary biomarkers, PCA3 and T2ERG, to a commonly used clinical risk calculator to predict PCa on biopsy. Our results show that the addition of PCA3 and T2ERG alone or in combination enhanced the performance of PCPT RC and CS PCPT RC in nonAA men. However, no model including biomarkers showed added utility in AA men in this cohort.
A number of studies have examined the utility of the PCPT RC in various cohorts. In 2011 Nam et al evaluated PCPT RC in concert with their own risk calculator in a prospective validation study. 13 They generated AUC values of 0.61 (95% CI 0.59e0.64) for the PCPT RC model, while their risk calculator, developed at Sunnybrook Health Sciences Center, gave an AUC of 0.67 (95% CI 0.65e0.69) and was found to be superior on decision curve analysis across thresholds. 13 Although AA men comprised only 5% of their study population, there was a significant OR of 3.3 (95% CI 1.9e5.7) associated with AA race. Of note the rate of biopsy positivity was high, similar to this cohort from the EDRN, at approximately 40%. In the external validation study of PCPT in SABOR the rate of positive biopsy among AA men was 49%.
14 Although the rate of positive biopsies in PCPT was lower (22%), it should be noted that only a small portion of men were African American (3.2%) and inclusion criteria required normal DRE and PSA 3 ng/ml or less. 11 Evaluation of PCPT RC in 10 international cohorts showed improved predictive ability of the calculator in the majority of cohorts. 15 However, a wide discrepancy of AUC values was generated and validity was questionable in several cohorts. Of note, only 3 cohorts included AA men, including the Cleveland Clinic, SABOR and Durham VA (Veterans Affairs) cohorts. In the SABOR and Durham VA cohorts the calculator was found to be well calibrated. 15 Indeed, in the SABOR cohort there was a higher AUC value for AA men of 0.80 (95% CI 0.68e0.92) compared to 0.66 (95% CI 0.61e0.71) in nonAA men.
14 This may reflect a lack of general applicability of PCPT RC to varying populations.
Several studies have shown racial variations in the expression of biomarkers in PCa and in PCa genomewide association studies. 16, 17 Current biomarkers that have been evaluated in larger series of men with or suspected of having PCa have shown varied results. However, none of these studies examined the racial variation that may exist for individual biomarkers and how it impacts clinical utility. PCA3 is a noncoding RNA found to be overexpressed in PCa tissue. 18 PCA3 is detectable in the urine of men with PCa and it is not influenced by factors such as prostate size and serum PSA level, which is a limitation of other biomarkers such as e2proPSA.
19e22 Most recently the EDRN study of PCA3 demonstrated the utility of a PCA3 score higher than 60 to predict an initial positive biopsy. 9 This study involved 13% AA men from multiple centers. Recent data have suggested the utility of PCA3 added to clinical tools such as the ERSPC (European Randomized Study of Screening for Prostate Cancer) multivariable prediction model. 23 Furthermore, several studies have shown the ability of urinary biomarkers such as PCA3 and T2ERG to improve sensitivity and specificity for screening for PCa. 7, 9, 23 To our knowledge this study is the first investigation of contemporary, validated biomarkers for PCa in racial subgroups. Similar to other studies, PCA3 added predictive utility to a baseline clinical risk calculator. This was seen in nonAA men for PCa and CS PCa. However, among AA men almost no change to the model was seen for PCa or CS PCa, although the baseline model showed higher predictive value. Similarly, urinary T2ERG was found to add significant value in nonAA men but not in AA men for PCa or CS PCa. The combination of the biomarkers again appeared to have utility in nonAA men alone. Furthermore, there was significant improvement when comparing the addition of PCA3 or T2ERG alone vs the combination of the 2 biomarkers.
Urinary T2ERG has been evaluated as a biomarker for predicting PCa on biopsy 24,25 and for baseline analysis in an active surveillance cohort.
26
These studies showed a benefit to T2ERG. The most recent evidence for urinary T2ERG comes from a study that clearly demonstrated clinical utility in the EDRN training cohort and validated this finding in an independent cohort. 8 Our findings, also in the EDRN training cohort, in nonAA men are similar to their findings, which is reassuring.
Two recent small studies examined nonvalidated novel PCa biomarkers. There appeared to be utility in AA men as well as in Caucasian men for GEMCaP (Genomic Evaluators of Metastatic Prostate Cancer) to predict biochemical disease, although no benefit was detected with ABCD3 gene expression for the prediction of metastatic disease in AA men.
27,28 Clearly, given the drive for precision medicine, novel and cancer specific biomarkers, and improved risk stratification for detection and management, it is important to remain cognizant that racial variations can and do exist. 5, 6, 16, 17 One strategy may not fit all, ie AA men who are known to have biological disease variability. Further assessment of other available biomarkers such as phi (Prostate Health Index) and the investigation of magnetic resonance imaging to detect anterior tumors may be more useful in African American men. Indeed, our findings serve as further impetus for true personalization in medicine.
The current study has several limitations. Men were followed only through index biopsy and, thus, if biopsy showed false-negative findings, which is a known distinct possibility, we did not have a means of capturing subsequent results. Although there is reasonable representation of AA men, the numbers are still low. The study was adequately powered to detect a 10% significant difference in predictive utility with the addition of biomarkers. Most importantly, this study is limited by the post hoc nature and subgroup analysis and, thus, the conclusions drawn can only be considered hypothesis generating. Lastly, the detection rate of PCa on biopsy in AA men may be underestimated due to a higher prevalence of anterior tumors and inherent under sampling. 29 Furthermore, PCA3 and T2ERG may not be accurate biomarkers for these lesions.
CONCLUSIONS
This study highlights important points. PCA3 and T2ERG add predictive value for detecting PCa and CS PCa in nonAA men. Also, PCA3 and T2ERG were not detected to add predictive value for PCa in AA men. Further validation of the hypothesis that the clinical utility of these biomarkers is restricted to specific racial subgroups is needed in large, well annotated cohorts. 
EDITORIAL COMMENT
It is critical to determine which men truly harbor indolent disease when deciding which men are suitable candidates for active surveillance for low risk prostate cancer. This is especially important for African American men, who have been shown to present with earlier, aggressive disease and are more likely to experience upgrading and biochemical failure after treatment when initially eligible for active surveillance. 1,2 A plethora of serum, urine and tissue based tests add incremental value to the predictive ability of the known risk factors of PSA, Gleason sum and clinical tumor classification. O'Malley et al present their analysis of 2 of these tests, PCA3 and T2ERG, among African American and nonAfrican American men in the training cohort of the Early Detection Research Network cohort. They found that adding PCA3 and T2ERG scores to the predicted cancer risk determined by the PCPT RC did not provide increased sensitivity in African American men.
While these authors performed a post hoc analysis to show that this was indeed statistically significant in this relatively small population, the results generate the hypothesis that there may be variable efficacy of the various biomarker based tests according to ethnicity. Clearly, adding test upon test in nontargeted fashion is not a viable method. The authors have determined that at least among African American men we can potentially avoid PCA3 and T2ERG.
